Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck

Radiotherapy and Oncology

Volumn 71, Issue 1, 2004, Pages 81-84

  Sykes, Andrew J ^a   Slevin, Nick J ^a   MacDougall, Robert H ^b   Ironside, Janet A D ^b   Mais, Kathleen L ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Cancer; Capecitabine; Head and neck; Radiotherapy

Indexed keywords

CAPECITABINE;

ADVANCED CANCER; ARTICLE; BEAM THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG TOLERABILITY; HEAD AND NECK CARCINOMA; HUMAN; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SQUAMOUS CELL CARCINOMA;

ADMINISTRATION, ORAL; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DRUG EVALUATION; HUMANS; MUCOUS MEMBRANE; OTORHINOLARYNGOLOGIC NEOPLASMS; PRODRUGS; RADIATION INJURIES; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; STOMATITIS;

EID: 1842422613     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2004.02.001     Document Type: Article

References (20)

1. Bourhis J., Calais G., Eschwege F. Chemoradiotherapy of carcinomas of the upper aerodigestive tract. Cancer Radiother. 2:1998;679-688.
2. Browman G.P., Cripps C., Hodson D.I., Eapen L., Sathya J., Levine M.N. Placebo controlled randomised trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol. 12:1994;2648-2653.
3. Browman G.P., Hodson D.I., Mackenzie R.J., Bestic N., Zuraw L. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer. A systematic review of the published literature with subgroup analysis. Head Neck. 23:2001;579-589.
4. Budman D.R., Meropol N.J., Reigner B., et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol. 16:1998;1795-1802.
5. Cox J.D., Stetz J., Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 31:1995;1341-1346.
6. Hoff P.M., Ansari R., Batist G., et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomised phase III study. J Clin Oncol. 19:2001;2282-2292.
7. Humerickhouse R.A., Dolan M.E., Haraf D.J., et al. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin Cancer Res. 5:1999;291-298.
8. Jeremic B., Shibamoto Y., Stanisavljevic B., et al. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomised trial. Radiother Oncol. 43:1997;29-37.
9. Kumamoto Y., Masuda M., Kuratomi Y., et al. FAR chemoradiotherapy improves laryngeal preservation rated in patients with T2N0 glottic carcinoma. Head Neck. 24:2002;637-642.
10. Lo T.C., Wiley A.L. Jr, Ansfield F.J., et al. Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomised study. Am J Roentgenol. 126:1976;229-235.
11. Lokich J., Fine N., Perri J., Bothe A.R. Jr. Protracted ambulatory infusion of 5-fluorouracil. Am J Clin Oncol. 6:1983;103-107.
12. Munro A.J. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer. 71:1995;83-91.
13. Sanchiz F., Milla A., Torner J., et al. Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys. 19:1990;1347-1350.
14. Sawada N., Ishikawa T., Sekiguchi F., Tanaka Y., Ishitsuka H. X-Ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human xenografts. Clin Cancer Res. 5:1999;2948-2953.
15. Schutter J., Cassidy J., Dumont E., et al. Preferential activation of capecitabine in tumour following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol. 45:2000;291-297.
16. Stupp R., Vokes E.E. 5-Fluorouracil plus radiation for head and neck cancer. J Infus Chemother. 5:1995;55-60.
17. Taylor S.G. IV, Murthy A.K., Griem K.L., et al. Concomitant cisplatin/5-FU infusion and radiotherapy in advanced head and neck cancer: 8-year analysis of results. Head Neck. 19:1997;684-691.
18. Twelves C., Boyer M., Findlay M., et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer. 37:2001;597-604.
19. Van Cutsem E., Findlay M., Osterwalder B., et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomised phase II study. J Clin Oncol. 18:2000;1337-1345.
20. Vokes E., Weichselbaum R., Lippman S., Hong W. Head and neck cancer. N Engl J Med. 328:1993;184-194.